Acta Veterinaria Eurasia
Research Article

Treatment of Feline Mammary Fibroepithelial Hyperplasia with the Combination of Aglepristone and Cabergoline

1.

İstanbul Üniversitesi Veteriner Fakültesi Doğum ve Jinekoloji Anabilim Dalı, 34320, Avcılar, İstanbul, Türkiye

2.

İstanbul Üniversitesi, Veteriner Fakültesi, Doğum ve Jinekoloji Anabilim Dalı, 34320, Avcılar, İstanbul

3.

The Institute of Medical Sciences, University of İstanbul, Cerrahpaşa 34303, İstanbul, Turkey

4.

Istanbul University, Faculty of Veterinary Medicine, Department of Gynecology and Obstetrics, Avcilar Campus, Istanbul, Turkey

5.

Department of Pathology, Faculty of Veterinary Medicine, Istanbul University, Avcılar, 34320, Istanbul, Turkey

Acta Vet Eurasia 2011; 37: 69-73
Read: 3118 Downloads: 830 Published: 24 December 2019

A case of fibroepithelial mammary hyperplasia in a two years old, intact, tabby female cat that showed oestrus 1 month ago was treated with the combination of aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) administrations. On the day of treatment, serum progesterone concentration was detected as 2,96 ng/ml and serum oestradiol concentration was below 5,0 pg/ml. The cat was treated with subcutaneous (SC) injections of aglepristone (Alizine, Virbac®) 15 mg/kg body weight (b.w.) on two subsequent days per week for three weeks and 5 |ig/kg b.w per a day, per os (PO) cabergoline (Galastop, Ceva®) administration was accompanied to this treatment on the first week for seven days. On the examination at the end of the third week, there was a marked regression of the mammary glands and the milk secretion ceased. Six weeks after the initiation of treatment, mammary glands were completely regressed and serum progesterone and oestradiol concentrations were 0.142 ng/ml, and <5pg/ml respectively. It is determined that in such cases which is associated with milk secretion, successful results can be achieved by using aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) together.

Files
EISSN 2619-905X